SCHEDULE: Farallon Capital Discloses 9.99% Stake in Minerva Neurosciences

Farallon Capital and its affiliated entities have reported a combined beneficial ownership of 9.99% in Minerva Neurosciences, Inc., including common stock and convertible preferred stock warrants.

Summary

• Farallon Capital Partners, L.P. and its affiliated entities (the "Reporting Persons") have filed a Schedule 13G for Minerva Neurosciences, Inc.
• The Reporting Persons collectively beneficially own 4,539,854 shares of Minerva Neurosciences, Inc. common stock.
• This aggregate ownership represents 9.99% of the company's outstanding common stock.
• The ownership includes 2,365,000 directly held common shares and the right to acquire an additional 2,174,854 common shares upon conversion of Series A Preferred Stock, which are acquirable through Preferred Tranche A Warrants.
• A beneficial ownership limitation prevents the conversion of additional Series A Preferred Stock if it would result in ownership exceeding 9.99% of the outstanding common stock.
• The filing was made under Rule 13d-1(c).

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of beneficial ownership by a significant institutional investor. While not directly positive or negative about company performance, a large institutional stake can be viewed favorably by the market as a signal of confidence.

Positives

• Significant institutional investment by Farallon Capital, indicating confidence in Minerva Neurosciences.
• The acquisition of convertible preferred stock warrants suggests a long-term strategic interest in the company.

Risks

• A beneficial ownership limitation of 9.99% restricts the full conversion of all 5,000 Preferred Tranche A Warrants, with 402 shares of Series A Preferred Stock currently not convertible due to this limitation.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may signal confidence and potentially stabilize the stock price.
• Company Management: A significant institutional shareholder like Farallon Capital could exert influence on strategic decisions, though the filing states the securities were not acquired for the purpose of changing or influencing control.

Key Dates

Keywords

Minerva Neurosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Preferred Stock, Warrants, MNRVA, Biotechnology, Pharmaceuticals